The NCI-H441 cell line was discovered in 1982, and derived from the p ericardial fluid of a male patient suffering from papillary adenocarcinoma. The cells express both major surfactant apoprotein (SP-A) and pulmonary surfactant protein (SP-B) with a doubling time of roughly 58 hours. The biomedical application of NCI-H441 widely ranges however its primary use is in lung cancer research. Altogen Biosystems provides a transfection reagent for NCI-H441 that optimizes the transfection efficiency. Transfection Reagent for NCI-H441 Cells (Lung Adenocarcinoma Cells, HTB-174)